• Accelerates AI‑driven transformation through expanded agentic AI and data engineering capabilities that underpin NTT DATA’s AI strategy
• Adds 1,000 Azure engineers and AI specialists to scale cloud and AI delivery capabilities
• Advances NTT DATA’s North America leadership position, scaling industry aligned AI led innovation across its cloud services and Microsoft Business Unit
• Builds on NTT DATA’s position as the fastest-growing Microsoft GSI partner, accelerating co-innovation in enterprise AI

PLANO, Texas–(BUSINESS WIRE)– NTT DATA, a global leader in AI, digital business and IT services, today announced it has signed a definitive agreement to acquire WinWire, an award-winning Microsoft partner specializing in Agentic AI, AI on Azure, data engineering and cloud-native development as foundational capabilities for enterprise AI. The acquisition strengthens NTT DATA’s position as a trusted partner to help organizations move beyond experimentation to operationalize AI at scale.

The acquisition further advances NTT DATA’s enterprise AI strategy as demand accelerates for AI-driven, cloud-native transformation. By expanding capabilities across data platforms, agentic AI and modern applications, NTT DATA is sharpening its ability to deliver production-ready AI solutions aligned to industry needs, reinforcing its leadership as Microsoft’s Global System Integrator (GSI) Growth Champion Partner of the Year.

Upon closing, WinWire will add more than 1,000 skilled Azure engineers and Microsoft specialists to NTT DATA, bringing deep experience across Microsoft environments, including Microsoft Fabric and Azure AI Foundry. This expanded talent base will strengthen NTT DATA’s global Microsoft practice and accelerate the delivery of next‑generation AI and cloud solutions.

These expanded capabilities, combined with WinWire’s proven industry specialization and long‑standing partnership with Microsoft, will enhance NTT DATA’s ability to deliver industry‑specific, cloud‑native and agentic AI solutions that address complex business challenges securely and consistently.

As enterprises increasingly demand AI platforms that support enterprise-wide transformation, industry analysts estimate the global AI market will grow from $390 billion to nearly $3.5 trillion over the next decade, highlighting the scale of AI adoption across enterprises.

By combining NTT DATA’s full-stack capabilities, industry expertise and managed services with WinWire’s specialized strengths in modern applications, data engineering and agentic AI, the company is uniquely positioned to help clients develop and scale AI solutions and unlock value from AI across the enterprise.

Headquartered in Santa Clara, California, with global delivery centers in India, WinWire is a trusted Microsoft partner and a six‑time Microsoft Partner of the Year Award winner and finalist, supporting enterprises in establishing AI‑ready digital foundations and scaling intelligent, cloud‑based solutions that deliver measurable business outcomes.

“The acquisition of WinWire is a decisive step in advancing our enterprise AI strategy and expanding our leadership in Microsoft Azure and AI-powered cloud transformation,” said Abhijit Dubey, CEO and Chief AI Officer, NTT DATA, Inc. “By combining WinWire’s deep expertise in cloud-native development and agentic AI with NTT DATA’s global scale, this positions us to lead the shift to enterprise AI, enabling clients to move from experimentation to enterprise-wide deployment and achieve meaningful business outcomes.”

Building on NTT DATA’s strategic partnership with Microsoft

The agreement builds on NTT DATA’s long-standing strategic partnership with Microsoft, combining its global scale with WinWire’s award-winning expertise in Azure-based AI and data transformation.

WinWire is also a member of the Microsoft Agentic Partner Alliance Program, further strengthening joint innovation and execution for industry-specific AI solutions.

WinWire will complement NTT DATA’s Global Business Unit for Microsoft Cloud, established to meet rising demand for secure, AI-driven enterprise transformation. The business unit spans Microsoft Cloud, security and AI, supported by more than 24,000 Microsoft certifications and operates across more than 50 countries.

The combined capabilities also reinforce NTT DATA’s ability to co-innovate and co-sell with Microsoft, building on its recognition as Microsoft’s 2025 Global System Integrator Growth Champion partner of the year.

“As a leading Microsoft Solutions Partner recognized through multiple awards over the years, we built WinWire with a clear focus on delivering meaningful Microsoft Azure and AI-led transformation for our enterprise clients,” said Ashu Goel, CEO, WinWire. “Joining NTT DATA marks an exciting new chapter, allowing us to extend our capabilities to a much broader global client base. Together, we are well positioned to accelerate innovation and shape the next wave of AI-driven transformation for our clients.”

“As enterprises look to unlock the full value of AI on Microsoft Azure, the role of skilled partners has never been more critical,” said Stephen Boyle, CVP, Enterprise Partner Solutions Microsoft. “By combining NTT DATA’s global scale with WinWire’s expertise in cloud-native development and agentic AI, this acquisition enhances our joint ability to co-innovate and deliver transformative solutions.”

Advancing client outcomes through cloud-native and AI-driven transformation

WinWire brings differentiated agentic AI, including its Agentic AI @ Scale framework, enabling the design and deployment of intelligent, autonomous systems embedded directly into enterprise workflows. Its portfolio of AI frameworks and industry accelerators helps organizations move from pilot initiatives to enterprise-scale AI adoption.

The combined portfolio spanning infrastructure, applications, data, AI and managed services will enable faster time to value and secure enterprise-scale AI deployment.

The transaction is subject to customary closing conditions and regulatory approvals. Rothschild & Co acted as the exclusive financial advisor to NTT DATA on the transaction.

About NTT DATA

NTT DATA is a $30+ billion business and technology services leader, serving 75% of the Fortune Global 100. We are committed to accelerating client success and positively impacting society through responsible innovation. We are one of the world’s leading AI and digital infrastructure providers, with unmatched capabilities in enterprise-scale AI, cloud, security, connectivity, data centers and application services. Our consulting and industry solutions help organizations and society move confidently and sustainably into the digital future. As a Global Top Employer, we have experts in more than 70 countries. We also offer clients access to a robust ecosystem of innovation centers as well as established and start-up partners. NTT DATA is part of NTT Group, which invests over $3 billion each year in R&D. Visit us at nttdata.com.

About WinWire

WinWire unleashes the Power of Agentic AI to deliver innovative solutions that help our customers gain competitive advantage. WinWire is at the forefront of enabling enterprises in the Healthcare and Software and Digital Platforms (SDP) sectors to embark on a transformative Agentic AI journey.

As a globally recognized, multi-award-winning Agentic AI firm, WinWire delivers a spectrum of AI-led digital transformational services that include:

• Agentic AI Services – Harness the power of Agentic AI to accelerate the Frontier Firm Journey.
• Foundational AI Services – Data Estate & BI Modernization for AI-Ready data.
• Operational AI Services – Manage, optimize, and evolve agents and enterprise applications leveraging Agentic AI systems to reduce costs & enhance agility.
• Visit us at: https://www.winwire.com/

View source version on businesswire.com: https://www.businesswire.com/news/home/20260515587720/en/

Contacts

Media Contacts

Lori Bosio | lori.bosio@nttdata.com

SES:

Société Anonyme

RCS Luxembourg B 81267

Notice is hereby given of the

Extraordinary General Meeting

of SES, Société Anonyme, to be held at the Company’s registered office at Château de Betzdorf,

L-6815 Betzdorf (the “Company“), Luxembourg, on

Wednesday 17 June 2026 at 3:00 p.m. CET

AGENDA

1. Attendance list, quorum and adoption of the agenda
2. Nomination of a secretary and of two scrutineers
3. Cancellation of shares purchased in connection with the buy-back programme of 2 November 2023, as amended on 2 May 2024, in accordance therewith and pursuant thereto – Reduction of the share capital in accordance with article 450-5 of the law of 10 August 1915 on commercial companies, as amended, by forty-four million nine hundred ten thousand seven hundred eighty euro (EUR 44,910,780) through the cancellation of thirty-five million nine hundred and twenty-eight thousand six hundred and twenty-four (35,928,624) shares divided into (i) twenty-three million nine hundred and fifty-two thousand four hundred and sixteen (23,952,416) class A shares without indication of a par value and (ii) eleven million nine hundred and seventy-six thousand two hundred and eight (11,976,208) class B shares without indication of a par value, which are held by SES Astra for and on behalf of the Company and which have been purchased in connection with the buy-back programme of 2 November 2023, as amended on 2 May 2024 and subsequent amendment of article 4, paragraph 1 of the articles of association of the Company
4. Decision to introduce indemnification provisions for the members of the board of directors of the Company and the members of the executive committee of the Company and subsequent addition of new paragraphs (F), (G) and (H) to article 9 of the articles of association of the Company
5. Decision to grant the board of directors of the Company discretion to determine the date of the annual general meeting of shareholders, provided it is held within six (6) months following the end of the financial year and subsequent amendment of article 19, first paragraph of the articles of association of the Company
6. Decision to determine the location of the annual general meeting of the shareholders of the Company and of any other general meetings of the shareholders of the Company and subsequent amendment of article 20 of the articles of association of the Company
7. Decision to amend the convening notice requirements for general meetings of shareholders so as to specify the publication obligations applicable thereto and subsequent amendment of article 21, first paragraph of the articles of association of the Company and addition of a new article 21, second paragraph to the articles of association of the Company
8. Decision to allow general meetings of shareholders to be held in hybrid mode and subsequent addition of a new article 22, fourth paragraph to the articles of association of the Company
9. Decision to allow the Company secretary to sign any copy or extract of the minutes of the meetings of the Board and subsequent amendment of article 14, second paragraph of the articles of association of the Company
10. Decision to determine the documents and items to be approved at the annual general meeting of the shareholders of the Company and subsequent amendment of article 27 of the articles of association of the Company
11. Decision to introduce disclosure obligations requiring the Company to make specified documents and information available to shareholders in connection with general meetings of shareholders and subsequent amendment of article 29 of the articles of association of the Company
12. Decision to determine the matters on which the auditor is called to report on at the annual general meeting of the shareholders of the Company and subsequent amendment of article 30 of the articles of association of the Company
13. Miscellaneous

LUXEMBOURG–(BUSINESS WIRE)– The board of directors of the Company recommends that you vote FOR agenda items 1-12 of the extraordinary general meeting of shareholders set forth above.

Attendance

The right of a shareholder to attend the Extraordinary General Meeting (“EGM“) and to participate in the vote will be determined at midnight (CET) on the fourteenth day preceding the EGM, i.e. 3 June 2026 (the “Registration Date“). If a Fiduciary Depositary Receipts (“FDR“) holder wishes to attend the meeting he has to be recorded as a shareholder in the share register of the Company prior to the Registration Date. Anyone not being a shareholder on the Registration Date may not attend or vote at the EGM.

Withdrawal of FDRs and Conversion into A-shares

An FDR holder who wants to convert FDRs into A-shares has to request this conversion in accordance with conditions 12 and 16 of the Terms and Conditions of the Amended and Restated Fiduciary Deposit Agreement dated 26 September 2001. This document is available at the Banque et Caisse d’Épargne de l’État, Luxembourg. No charge for conversion will be requested for natural persons who are not yet shareholders of category A and who proceed to a conversion of a maximum of 10,000 FDRs into A-shares, allowing them to participate in the EGM of 17 June 2026.

The latest date for withdrawing FDRs and converting into A-shares for attendance at the EGM is 3 June 2026 at 4:30 p.m. CET. Shareholders who have converted their FDRs into A-shares prior to that date will receive a copy of the EGM documents and details required to attend the EGM. Please feel free to contact Banque et Caisse d’Épargne de l’État, Luxembourg, for further queries in this respect, at the following address: securitisation.irm@spuerkeess.lu.

Voting instructions

The FDR holder is entitled, subject to any applicable provisions (e.g. Luxembourg law, articles of association, shareholders’ thresholds and concession agreement) to instruct the Fiduciary via his bank as to the exercise of the voting rights by means of a voting certificate available on request at the bank where the FDRs are held.

In order for the voting instructions to be valid, the voting certificate form must be completed and duly signed by the FDR holder or, as the case may be, the beneficial owner. Please feel free to contact Banque et Caisse d’Épargne de l’État, Luxembourg, for further queries in this respect at the following address: securitisation.irm@spuerkeess.lu.

Upon receipt of the voting certificate on or before the date determined by the Fiduciary (being at the latest 15 June 2026 at 3:00 p.m. CET) with such certification and evidence as requested by the Fiduciary or by the Company, the Fiduciary shall transmit to the Company the relevant certifications and supporting evidence and the Company shall verify whether the relevant holders of FDRs or the beneficial owners thereof would qualify as an A-shareholder of the Company if in lieu of FDRs they would hold the corresponding number of A-shares.

If within eight Luxembourg business days from the receipt of such certification and supporting evidence, the Company has not notified the Fiduciary of its rejection of the request of a holder to exercise its voting rights pertaining to the A-shares underlying its FDRs, the Company shall be deemed to have accepted the relevant voting request.

After receipt of the written approval of the voting request by the Company, the Fiduciary shall vote or cause to be voted in accordance with the instructions set forth in such requests. The Fiduciary may designate and appoint authorized representatives to attend the meeting and vote on behalf of the FDR holders.

The voting instructions are deemed to be irrevocable and definitive 48 hours prior to the time for which the meeting has been convened, i.e. at the latest on 15 June 2026 at 3:00 p.m. CET. If the Fiduciary has not received voting instructions from the FDR holder, the Fiduciary shall be deemed to have been instructed to vote in the manner proposed by the Board of Directors in the relevant meeting.

There will be no vote under item 13. Miscellaneous.

Amendments to the Agenda

One or more shareholders owning together at least 5% of the share capital of SES have the right to add items to the agenda of the EGM and may deposit draft resolutions regarding items listed on the agenda or proposed to be added to the agenda. This request will need to be received at the latest the twenty-second day preceding the EGM, i.e. 26 May 2026, and made in writing via post (SES, Attn. Ms Sarah Gavin, Château de Betzdorf, L-6815 Betzdorf, Luxembourg) or email (shareholders@ses.com) and will need to include a justification or draft resolution to be adopted at the EGM. The written request will need to include a contact address (post or email) to which the Company can confirm receipt within 48 hours from the receipt of the request.

At the latest fifteen days preceding the EGM, i.e. 2 June 2026, the Company will then publish a revised agenda.

Documents made available by SES

Documents made available by the Company (including the draft resolutions proposed to be adopted at the EGM) for the purpose of this meeting may be inspected during normal working hours by the FDR holders at the offices of the Fiduciary, Banque et Caisse d’Épargne de l’État, Luxembourg, Issuer Services/IRM, 16 rue Zithe, L-2954 Luxembourg, or alternatively at the offices of the Listing Agents, BGL BNP Paribas S.A., 50 avenue J.F. Kennedy, L-2951 Luxembourg, and Société Générale, GSSI/GIS/CMO/AGL, 32 rue du Champ de Tir, F-44312 Nantes Cedex 3, France, and are available on the following websites: www.ses.com and www.spuerkeess.lu/SES.

Please feel free to contact SES for further queries in this respect at the following address: shareholders@ses.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260514124904/en/

Contacts

shareholders@ses.com

TALLINN, Estonia–(BUSINESS WIRE)– AS Graanul Invest (“Graanul” or the “Company”), Europe’s largest producer of sustainable wood pellets used for electricity and heat production, today announces energy industry veteran Lars Christian Bacher will be joining the business as Chief Executive Officer, effective 18 May. Bacher will drive the Company’s growth across Europe as Graanul doubles down on its strategy to provide its customers with sustainable fuel to enable the production of renewable, dispatchable power and heat. Outgoing Chief Executive Nicholas Dottino will support Bacher with his transition to his new role as an advisor to Apollo on infrastructure and energy investments.

Bacher joins Graanul having previously worked at Norwegian multinational energy company Equinor as a member of the Executive Committee for over eight years, including two years as Chief Financial Officer, where he had responsibility for managing financial operations and strategic planning. Prior to this, he was executive Vice President, Development and Production International (DPI), for Statoil ASA, where his responsibilities included production, operating and capital expenditure, geographic expansion, culture building and safety and security. Most recently Bacher served as Chief Executive Officer at Morrow Batteries from 2022-2025.

Chair of Graanul’s Supervisory Board and Apollo Partner, Brad Fierstein, commented: “We are delighted to welcome an energy industry leader of Lars Christian’s caliber to Graanul at an exciting time as the company looks to accelerate its growth trajectory, while continuing to play an essential role in the European energy industry. I would also like to take this opportunity to sincerely thank Nicholas for his many accomplishments and contributions to Graanul since joining the business.”

Incoming Graanul Invest CEO Lars Christian Bacher, added: “I am thrilled to be joining Graanul, a business that is playing an integral role supporting European energy security, at an important moment for the continent. I look forward to working alongside our talented leadership team as we continue to serve our customers, leading utilities across the continent, and engaging our teams in our production facilities across the Baltics and US”.

Notes to Editors

About Graanul Invest

Graanul is the largest sustainable wood-pellet manufacturer in Europe, focusing primarily on the European pellet market. The wood pellets produced are low-carbon alternative fossil fuels that are used for renewable power generation, commercial and residential heating, as well as combined heating and power applications. Graanul operates across Estonia, Latvia, Lithuania and the United States.

About Lars Christian Bacher

Lars Christian Bacher brings nearly three decades of experience in the global energy sector, including investing across the European energy industry. He started his career at Equinor, rising through a series of senior positions to Chief Financial Officer. Prior to this, he was executive Vice President, Development and Production International (DPI), for Statoil ASA, having spent over 25 years with the company. During his tenure as CEO of Morrow Batteries, a European lithium-ion battery manufacturer, he oversaw the company’s scale up, secured funding from Innovation Norway, and raised new equity to guide Morrow through an intensive phase of construction, research and development. He holds a Master of Science in Chemical Engineering from the Norwegian School of Technology and a Master of Finance from the Norwegian School of Economics.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260514182250/en/

Contacts

Media contacts
FGS Global for Graanul Invest / graanulinvest@fgsglobal.com

• Demands for privacy and sovereignty expose limits of architectures built for centralized and borderless data flows.
• Data jurisdiction has become a core design parameter, shifting away from globally integrated systems to regionally bounded architectures.
• Organizations that redesign early are gaining a measurable edge in AI readiness and scale.

TOKYO & LONDON–(BUSINESS WIRE)– NTT DATA, a global leader in AI, digital business and technology services, today released new research showing that enterprise AI is outgrowing the architecture and infrastructure beneath it as data privacy and sovereignty requirements tighten. The research finds a widening split between enterprises that are redesigning AI for control, locality and security, and organizations still layering AI into environments that were not built to support these requirements.

For years, enterprise architecture moved data across systems, clouds, applications and borders with increasing speed and efficiency. AI is exposing the limits of that model. Sensitive data must be protected, workloads must run inside defined jurisdictions, and models must be governed under tighter controls. Data cannot always move with the speed and fluidity many AI systems expect, making jurisdiction a core architectural constraint. As a result, private and sovereign AI have become critical considerations.

NTT DATA’s 2026 Global AI Report: A Playbook for Private and Sovereign AI reveals a gap between what organizations know they need and what they are ready to build:

• More than 95% of respondents say private and sovereign AI are important, but only 29% are prioritizing sovereign AI in a concrete, near-term way.
• About 35% of CAIOs identify building, integrating and managing complex AI models in private or sovereign environments as their top barrier to adoption, and nearly 60% of AI leaders cite cross-border data restrictions as a major challenge.
• Only 38% report high confidence in their cloud security posture—a critical foundation for both private and sovereign AI.

Private and sovereign AI are related, but distinct. Private AI focuses on protecting sensitive enterprise data, controlling access and limiting exposure. Sovereign AI focuses on ensuring that AI systems, data and operating environments meet jurisdictional, regulatory or national and regional control requirements.

“As AI evolves, private and sovereign approaches are testing enterprise readiness,” said Abhijit Dubey, CEO and Chief AI Officer, NTT DATA, Inc. “The organizations that are succeeding are going beyond regulatory compliance and risk mitigation. They are building the operating foundation for AI that can perform across markets, jurisdictions and business environments. Our research shows AI leaders are pulling ahead by treating architecture, infrastructure and governance as strategic requirements.”

The report identifies five shifts defining the next phase of enterprise AI:

1. AI is running into a wall – and it’s not the model. The constraint is no longer model performance alone. AI now requires greater control over compute, data access, security and locality—exposing the limits of infrastructure built for centralized, borderless data flows.
2. Data jurisdiction is now an architectural constraint. Data can still move, just not the way AI needs. Because AI depends on continuous access and movement of data, jurisdiction is shaping where data lives, where models run and how systems are designed and governed.
3. Everyone sees the shift—few are acting on it. More than 95% of organizations recognize the importance of private and sovereign AI, but only around one-third are prioritizing sovereign AI in a concrete, near-term way.
4. Leaders are redesigning early and moving decisively—creating competitive divergence. Leaders are moving decisively, aligning infrastructure, governance and operating models early. This is enabling them to move faster from pilots to scaled deployments, while others struggle to adapt.
5. Private and sovereign AI sounds like independence—in practice, they rely on tightly orchestrated ecosystems. More than half of organizations cite integration complexity as their top challenge. As organizations push for greater control, they are also increasing the complexity and interdependence of their AI ecosystem partners coordinating across the stack.

Together, private and sovereign AI are changing how AI systems are built, governed and scaled. Organizations that redesign early are better positioned in regulated, distributed and data-sensitive environments. Those that layer AI into architectures that were not built for control, locality or data-flow constraints may struggle to turn their AI ambition into durable value.

The report draws on two studies engaging a total of nearly 5,000 senior decision-makers across more than a dozen industries, more than 30 markets and five regions. It is part of NTT DATA’s global research series on strategies that separate AI leaders from the market.

About NTT DATA

NTT DATA is a $30+ billion business and technology services leader, serving 75% of the Fortune Global 100. We are committed to accelerating client success and positively impacting society through responsible innovation. We are one of the world’s leading AI and digital infrastructure providers, with unmatched capabilities in enterprise-scale AI, cloud, security, connectivity, data centers and application services. Our consulting and industry solutions help organizations and society move confidently and sustainably into the digital future. As a Global Top Employer, we have experts in more than 70 countries. We also offer clients access to a robust ecosystem of innovation centers as well as established and start-up partners. NTT DATA is part of NTT Group, which invests over $3 billion each year in R&D.

Visit us at nttdata.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20260514228841/en/

Contacts

NTT DATA, Inc.

Dan.Smith@nttdata.com

LONDON & NEW YORK–(BUSINESS WIRE)– Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will attend the RBC Capital Markets Global Healthcare Conference on May 19-20, 2026 and will participate in a fireside chat on May 19 at 10:00am ET.

A live audio webcast of this event will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event.

About Compass Pathways

Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways to help and empower people with serious mental health conditions who are not helped by existing treatments. We are pioneering a new paradigm for treating mental health conditions focused on rapid and durable responses through the development of our investigational COMP360 synthetic psilocybin treatment, potentially a first in class treatment. COMP360 has Breakthrough Therapy designation from the US Food and Drug Administration (FDA) and has received Innovative Licensing and Access Pathway (ILAP) designation in the UK for treatment-resistant depression (TRD).

Compass is headquartered in London, UK, with offices in New York in the US. We envision a world where mental health means not just the absence of illness but the ability to thrive.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260514611471/en/

Contacts

Enquiries

Media: Dana Sultan-Rothman, media@compasspathways.com
Investors: Stephen Schultz, stephen.schultz@compasspathways.com, +1 401 290 7324

MUNICH–(BUSINESS WIRE)– Global technology corporation FPT officially cut the ribbon on its latest office in Germany. This milestone reinforces the company’s long-term commitment to delivering AI-driven services to its growing customer base across Germany and the wider European market.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260514689341/en/

The inauguration ceremony was attended by H.E. Mr Nguyen Dac Thanh, Ambassador of Vietnam to Germany, alongside representatives from the local government, FPT executives, and key partners.

Situated in one of Europe’s most dynamic technological and manufacturing hubs, the Munich office strengthens FPT’s delivery capabilities and enables faster, more scalable engagement across the region. The move underscores the company’s strategic focus on investing in key innovation hubs to meet rising demand for AI transformation and accelerate time-to-value for clients.

“Our expanded presence in Munich allows us to stay in close proximity with our clients, especially those in manufacturing, automotive, and high-tech sectors. By being a part of this dynamic innovation ecosystem, FPT is ready to support businesses in the AI-led transformation”, said Dzung Tran, FPT Software Senior Vice President and FPT Europe Chief Executive Officer, FPT Corporation.

Highlighting FPT’s dedication to accompanying regional and global businesses, the event featured an exclusive conference focusing on practical AI strategies and applications across high-growth industries. Senior leaders and experts from FPT’s partners and clients such as E.ON, Covestro, Schaeffler, Allego, AWS, and OutSystems, joined the dialogues on harnessing AI for a sustainable future and establishing governance frameworks to ensure safe and scalable deployment of the technology.

“As the world navigates disruptions from geopolitical shifts and AI, FPT is committed to being your trusted partner. Backed by our AI-first approach and a global workforce of more than 30,000 AI-augmented engineers, we will bridge world-class innovation and a robust talent pool from Vietnam to businesses and organizations in Europe, to achieve operational resilience and sustainable development together,” said Mdm. Chu Thi Thanh Ha, FPT Software Chairwoman, FPT Corporation.

“Rooted in Vietnam’s culture of agility, adaptability, and a strong spirit of collaboration, FPT will continue to bring not only technological expertise but also a partnership mindset grounded in trust, long-term commitment, and continuous innovation,” she added.

Bolstering its market presence for over a decade, FPT has established partnerships with more than 150 leading European enterprises, including RWE, Viessmann, Volvo Cars, Valeo, and ebm-papst. Fueled by both organic growth and strategic acquisitions, the company continues to scale its operational footprint, providing comprehensive IT services and deep domain expertise to accelerate digital transformation across Europe.

About FPT Corporation

FPT Corporation (FPT) is a globally leading Vietnam-headquartered technology and IT services provider, with operations spanning more than 30 countries and territories. Over more than three decades, FPT has consistently delivered impactful solutions to millions of individuals and tens of thousands of organizations worldwide. With a strong focus on mastering strategic technologies, FPT continues to drive innovation across industries. As an AI-first company, FPT is committed to elevating Vietnam’s position on the global tech map and delivering world-class AI-enabled solutions for global enterprises. In 2025, FPT reported a total revenue of USD 2.66 billion and a workforce of over 54,000 employees across its core businesses. For more information about FPT’s global IT services, please visit https://fptsoftware.com/

View source version on businesswire.com: https://www.businesswire.com/news/home/20260514689341/en/

Contacts

Media Contact
Mai Duong (Ms.)

FPT Corporation

FPT Software PR Manager

MCP.PR@fpt.com

AB InBev Holds 8 of the Top 10 Most Valuable Beer Brands Globally

LONDON–(BUSINESS WIRE)– Corona global has been recognized as the most valuable beer brand in the world for the third consecutive year in Kantar’s BrandZ 2026 Most Valuable Global Brands report, released today. Eight out of the top ten most valuable global beer brands belong to AB InBev (Brussel:ABI) (BMV:ANB) (JSE:ANH) (NYSE:BUD), according to the report ranking the best brands in the world.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260513211378/en/

In 2025, Corona led AB InBev’s performance, increasing revenue by 8.3% outside of its home market with double-digit volume growth in 30 markets, while Corona Cero delivered strong double-digit volume growth. As the brand celebrated its 100th anniversary, Corona launched its global “Corona 100” platform, including a multi-year sponsorship of a renowned concert at Copacabana Beach in Rio de Janeiro. Strong momentum continued in Q1 2026, with AB InBev delivering all-time high revenues and volume growth, led by Corona, which grew 16% outside its home market following a successful debut as the world’s first global beer sponsor of The Winter Olympics.

In Kantar’s BrandZ 2026 rankings, Corona is followed by Budweiser as the second most valuable beer brand in the world, with Modelo, Michelob ULTRA, Brahma, Bud Light, Skol and Stella Artois helping AB InBev secure 8 of the world’s top 10 most valuable beer brands.

“Corona’s recognition as the most valuable beer brand in the world for three consecutive years reflects our approach to building brands for long-term, sustainable growth,” said Marcel Marcondes, Global Chief Marketing Officer. “For AB InBev to have 8 of the top 10 beer brands in Kantar BrandZ’s 2026 rankings underscores the focus, consistency and creative effectiveness of our teams and partners around the world.”

BrandZ charts the way in which global brands have continued to evolve and innovate. Now in its 21st edition, it spotlights the importance of building meaningful difference where a brand meets consumer needs, stands out from competitors and remains top-of-mind in its sector for a prolonged period.

“Corona’s performance in Kantar BrandZ’s global rankings shows what strong brands achieve when they are built with discipline, over time. Brand value comes from being meaningfully different in ways people recognise, showing up consistently and staying relevant as the world changes. That doesn’t change, even as technology introduces new ways for people to discover and interact with brands. Marketers still need to make clear decisions about what their brand stands for and how it shows up in the real world. That’s something the Corona team continues to get right,” said Paul Zwillenberg, CEO of Kantar.

Kantar BrandZ is a global ranking that assesses brand value by combining financial data and extensive brand equity research, offering an in-depth view of over 22,000 brands in 54 markets.

About AB InBev

Anheuser-Busch InBev (AB InBev) is a publicly traded company (Euronext: ABI) based in Leuven, Belgium, with secondary listings on the Mexico (MEXBOL: ANB) and South Africa (JSE: ANH) stock exchanges and with American Depositary Receipts on the New York Stock Exchange (NYSE: BUD). As a company, we dream big to create a future with more cheers. We are always looking to serve up new ways to meet life’s moments, move our industry forward and make a meaningful impact in the world. We are committed to building great brands that stand the test of time and to brewing the best beers using the finest ingredients. Beer is the drink for moderation, and for over a century, AB InBev has championed responsible drinking. We are committed to providing our consumers with Balanced Choices to enjoy on any occasion. We also invest in marketing that aims to reinforce positive behaviors, and we work with communities, customers, and partners to promote responsible consumption through evidence-based initiatives.

Our diverse portfolio of well over 400 beer brands includes global brands Budweiser^®, Corona^®, Stella Artois^® and Michelob Ultra^®; multi-country brands Beck’s^®, Hoegaarden^® and Leffe^®; and local champions such as Aguila^®, Antarctica^®, Bud Light^®, Brahma^®, Cass^®, Castle^®, Castle Lite^®, Cristal^®, Harbin^®, Jupiler^®, Modelo Especial^®, Quilmes^®, Victoria^®, Sedrin^®, and Skol^®. Our brewing heritage dates back more than 600 years, spanning continents and generations. From our European roots at the Den Hoorn brewery in Leuven, Belgium. To the pioneering spirit of the Anheuser & Co brewery in St. Louis, US. To the creation of the Castle Brewery in South Africa during the Johannesburg gold rush. To Bohemia, the first brewery in Brazil. Geographically diversified with a balanced exposure to developed and developing markets, we leverage the collective strengths of approximately 137 000 colleagues based in more than 40 countries worldwide. For 2025, AB InBev’s reported revenue was 59.3 billion USD (excluding JVs and associates).

About Kantar

Kantar is the world’s leading marketing data and analytics business. We deliver the intelligence needed to power brand growth.

We provide the signals that help organisations act quickly and confidently. We empower brands to make effective marketing decisions based on predictive evidence. And we help them craft powerful growth strategies rooted in the connection between consumers, brands and enterprise value. All this is powered by our uniquely robust human and synthetic data, our unrivalled IP, our AI-native platform and the team of global brand experts that bring this all together.

About Kantar BrandZ

Kantar BrandZ is the global currency when assessing brand value, quantifying the contribution of brands to business’ financial performance. Kantar’s annual global and local brand valuation rankings combine rigorously analysed financial data, with extensive brand equity research. Since 1998, BrandZ has shared brand-building insights with business leaders based on interviews with 4.6 million consumers, for over 22,000 brands in 54 markets. Discover more about Kantar BrandZ here.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260513211378/en/

Contacts

AB InBev contact
media.relations@ab-inbev.com

News summary:

• Service providers are replacing aging in-home Wi-Fi equipment as expectations rise and competitive pressure accelerates next-generation Wi-Fi adoption
• SDG 8700 Series now supports Wi-Fi 7 across the full range of mass-market residential to premium SMB service offerings
• Expanded portfolio delivers scalable, high-quality Wi-Fi 7 experiences while maintaining operational consistency and regulatory readiness

HUNTSVILLE, Ala.–(BUSINESS WIRE)– Adtran today announced an expansion of its SDG 8700 Series, extending Wi-Fi 7 across a broader range of residential service tiers and deployment models. The expanded portfolio introduces new 2.5Gbit/s and 10Gbit/s Wi-Fi 7 platforms designed to support the full spectrum of multigigabit services – from entry-level offerings to premium tiers – across residential, SMB, MDU and community Wi-Fi deployments. As service providers enter a new access refresh cycle, Wi-Fi 7 is rapidly becoming a baseline requirement rather than a premium differentiator. Adtran’s expanded SDG 8700 portfolio enables providers to deploy next-generation Wi-Fi more broadly and consistently without compromising subscriber experience or changing operational models. The launch also builds on the FCC’s recent conditional approval of Adtran’s SDG portfolio, supporting continued broadband rollout momentum.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260513003660/en/

Adtran’s new SDG 8700 devices will help service providers deliver Wi-Fi 7 at scale.

“Service providers are telling us the decision to adopt Wi-Fi 7 has already been made. The real challenge is deploying it widely and consistently,” said Christoph Glingener, CTO of Adtran. “Competitive pressure is accelerating Wi-Fi 7 standardization, and providers want to deliver high-quality experiences to their full subscriber base, not just premium tiers. Our SDG 8700 Series delivers Wi-Fi 7 at scale, offering a clean path from legacy gateway refresh to next-generation in-home experiences while maintaining consistency across provisioning, management and support.”

Adtran’s expanded SDG 8700 Series includes its third-generation dual-band and tri-band Wi-Fi 7 gateways. The new devices support 2.5GbE and 10GbE connectivity options, along with optional voice configurations. Built on Adtran’s SmartOS platform, the gateways operate within a unified software environment shared across the SDG portfolio, simplifying upgrades, testing and operational support. Native support for Intellifi^®, TR-369 and Plume gives service providers the flexibility to align with their preferred subscriber experience platforms while maintaining consistent operations, simplified lifecycle management and long-term platform continuity across residential networks.

“In-home connectivity is undeniably where broadband experience is being defined, which means platforms must evolve cleanly across technology generations and deployment scenarios,” commented Eric Presworsky, GM of subscriber solutions at Adtran. “Our SDG 8700 Series expansion reflects a wider portfolio strategy centered on scalable, open platforms, software continuity, operational flexibility and consistency. By enabling Wi-Fi 7 standardization across service tiers today, we’re helping providers modernize at their own pace while building a strong, stable foundation for future broadband innovation.”

About Adtran

ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the majority shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and X.

Published by 

ADTRAN Holdings, Inc. 

www.adtran.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20260513003660/en/

Contacts

For media
Gareth Spence

+44 1904 699 358

public.relations@adtran.com

For investors
Rob Fink

+1 646 809 4048

investor.relations@adtran.com

• FDA granted Compass NDA rolling submission and review request, based on strength of Phase 3 data
• CNPV awarded for COMP360 in TRD, further accelerating momentum
• 26-week (Part B) data from COMP006, expected in early Q3 2026
• Final NDA submission on track for Q4, aligned with Company’s previously defined accelerated timing to be launch ready by end of year
• Successful financing and warrant exercises resulted in strong cash position of $466 million at end of first quarter, providing cash runway well beyond launch and into 2028

LONDON & NEW YORK–(BUSINESS WIRE)– Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported first quarter 2026 financial results and business highlights.

“With regulatory acceleration unfolding, we are working diligently towards our goal of completing the filing of a robust clinical package by Q4 and securing COMP360 approval,” said Kabir Nath, Chief Executive Officer of Compass Pathways. “COMP360 represents a fundamentally different approach for patients with treatment resistant depression, unlike any other treatment approved today. Its transformative clinical profile has the potential to change what patients can expect in terms of both rapid and durable relief, and we are ready to deliver for those who have waited far too long for better options.”

Business Highlights

Accelerated regulatory path

Approval timelines are tracking to Compass’ fastest projected expectations, supported by regulatory acceleration including a rolling New Drug Application (NDA) submission and the Commissioner’s National Priority Review Voucher (CNPV).

• NDA rolling submission underway:
  • FDA granted Compass NDA rolling submission and review request, based on strength of positive Phase 3 data.
  • Rolling submission and review are underway, with sections of the NDA already submitted.
  • 26-week (Part B) data from COMP006, expected in early Q3 2026.
  • The final NDA submission remains on track for Q4, aligned with the Company’s previously defined accelerated timing.
• Post-NDA filing momentum:
  • CNPV awarded for COMP360, Compass’ proprietary formulation of synthetic psilocybin for TRD, which has the potential to accelerate filing review time to be completed within 1-2 months.
  • White House Executive Order on psychedelics treatments directs the Drug Enforcement Administration (DEA) to initiate and complete review of psychedelic treatment that has successfully completed Phase 3 trials so that rescheduling may proceed as quickly as possible.

Advancing toward commercial launch

• Launch readiness:
  • Compass will be launch ready by the end of the year and has assembled a highly experienced commercial leadership team.
  • The team is advancing comprehensive launch preparedness efforts, including KOL and HCP education, payer engagement, and ongoing initiatives to support a timely federal and state rescheduling process.
• Delivery infrastructure readiness:
  • COMP360 is expected to fit seamlessly across diverse healthcare settings within the current infrastructure of over 7,300 centers¹ offering multi-hour treatments
  • Treatment centers are growing rapidly, and existing centers are already scaling in anticipation of a COMP360 launch and additional multi-hour psychedelic treatments coming to market.

COMP360’s transformative clinical profile

• COMP360 has the potential to offer a highly differentiated, transformative clinical profile and is expected to be a blockbuster opportunity.
• COMP360 is the first classic psychedelic² to consistently achieve a highly statistically significant result and clinically meaningful effect in 3 large late-stage trials involving more than 1,000 participants living with TRD, with a generally well-tolerated and safe profile.
• COMP360 demonstrates effects as quickly as within one day after administration with durability lasting at least through 6 months for those who achieve a clinically meaningful response after one or two doses.

Financial Highlights

• Research and development expenses were $26.5 million for the three months ended March 31, 2026, compared with $30.9 million during the same period in 2025. The decrease was primarily driven by lower development expenses, reflecting reduced clinical trial costs as our Phase 3 program for COMP360 psilocybin therapy in TRD progresses toward completion, as well reduced discovery program expenses following the termination of certain programs in connection with the reorganization that took place in the fourth quarter of 2024 and the related contract terminations in 2025.
• General and administrative expenses were $16.4 million for the three months ended March 31, 2026, compared with $18.7 million during the same period in 2025. The decrease was primarily due to lower legal and professional fees, driven by higher financing-related costs in 2025, including those associated with warrant issuances, which were expensed as incurred, whereas a greater portion of such costs in 2026 were capitalized. This decrease was partially offset by increased consulting and legal advisory expenses.
• Net income for the three months ended March 31, 2026, was $91.2 million, or $0.71 net income per share (basic) and $0.30 net loss per share (diluted), compared with a net loss of $17.9 million, or $0.20 net loss per share (basic) and $0.24 net loss per share (diluted), during the same period in 2025. The increase in net income was primarily driven by a $130.9 million non-cash gain on fair value adjustment related to our warrants, compared with $19.5 million during the same period in 2025. As the fair value of the warrants fluctuates with our share price, this adjustment can result in significant variability in our reported net income or net loss.
• Cash and cash equivalents were $466.0 million as of March 31, 2026, compared with $149.6 million as of December 31, 2025.
• Debt was $50.5 million as of March 31, 2026, compared with $31.6 million as of December 31, 2025.

Financial Guidance

The current cash position is expected to be sufficient to fund operating expenses and capital expenditure requirements into 2028.

About Compass Pathways

Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways to help and empower people with serious mental health conditions who are not helped by existing treatments. We are pioneering a new paradigm for treating mental health conditions focused on rapid and durable responses through the development of our investigational COMP360 synthetic psilocybin treatment, potentially a first in class treatment. COMP360 has Breakthrough Therapy designation from the US Food and Drug Administration (FDA) and has received Innovative Licensing and Access Pathway (ILAP) designation in the UK for treatment-resistant depression (TRD).

Compass is headquartered in London, UK, with offices in New York in the US. We envision a world where mental health means not just the absence of illness but the ability to thrive.

Forward-looking statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. In some cases, forward-looking statements can be identified by terminology such as “may”, “might”, “will”, “could”, “would”, “should”, “expect”, “intend”, “plan”, “objective”, “anticipate”, “believe”, “contemplate”, “estimate”, “predict”, “potential”, “continue” and “ongoing,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements include express or implied statements relating to, among other things, statements regarding our expectations regarding our financial guidance; our business strategy and goals; our expectations and projections about the company’s future cash needs and financial results; our expectations regarding the safety or efficacy of our investigational COMP360 psilocybin treatment, including as a treatment of TRD or PTSD; our plans and expectations regarding our clinical trials, including our phase 3 trials in TRD and our phase 2b/3 trial in PTSD; our expectations regarding the time periods for the release of data from Part B of the COMP006 Phase 3 trial for TRD; any implication that past results will be predictive of future results; our expectations regarding the timing of our rolling submission of a new drug application, or NDA, for COMP360 psilocybin treatment in TRD and the timing of the review by the Food and Drug Administration, or FDA, of such NDA, including potential acceleration due to the grant of rolling review and award of a Commissioner’s National Priority Voucher, or CNPV, for COMP360 psilocybin treatment in TRD; the potential for the pivotal phase 3 program in TRD to support regulatory filings and approvals on an accelerated basis or at all; our expectations regarding potential commercial launch timelines and our commercial readiness; our efforts and our ability to obtain regulatory approval and adequate coverage and reimbursement; our ability to transition from a clinical-stage to a commercial-stage organization and effectively launch a commercial product, if regulatory approval is obtained, on an accelerated timeline or at all; and our expectations regarding the benefits of our investigational COMP360 psilocybin treatment, including as a treatment of TRD or PTSD. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Compass’s control and which could cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by these forward-looking statements.

These risks, uncertainties, and other factors include, among others: uncertainties associated with risks related to clinical development which is a lengthy and expensive process with uncertain outcomes, and therefore our clinical trials may be delayed or terminated and may be more costly than expected; the full results and safety data from our Phase 3 clinical trials in TRD may not be consistent with the preliminary results to date; our need for additional funding to achieve our business goals and if we are unable to obtain this funding when needed and on acceptable terms, we could be forced to delay, limit or terminate our clinical trials; that the rolling review process and/or the Commissioner’s National Priority Voucher pilot program may not actually lead to a faster FDA review or approval process; our efforts to obtain FDA approval, or approval from regulatory authorities in other jurisdictions, for our investigational COMP360 psilocybin treatment on an accelerated basis, or at all, may be unsuccessful; our efforts to commercialize and obtain coverage and reimbursement for our investigational COMP360 psilocybin treatment, if approved, may be unsuccessful; the risk that our strategic collaborations will not continue or will not be successful; and our ability to retain key personnel; and those risks and uncertainties described under the heading “Risk Factors” in Compass’s most recent annual report on Form 10-K or quarterly report on Form 10-Q, the prospectus supplement related to the proposed public offering we plan to file and in other reports we have filed with the U.S. Securities and Exchange Commission (“SEC”), which are available on the SEC’s website at www.sec.gov. Except as required by law, Compass disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Compass’s current expectations and speak only as of the date hereof.

References

1. Data on file
2. For the definition of classic psychedelic, see Vollenweider, F.X. and Smallridge, J.W., 2022. Classic psychedelic drugs: update on biological mechanisms. Pharmacopsychiatry, 55(03), pp.121-138

Enquiries

Media: Dana Sultan-Rothman, media@compasspathways.com

Investors: Stephen Schultz, stephen.schultz@compasspathways.com, +1 401 290 7324

View source version on businesswire.com: https://www.businesswire.com/news/home/20260513826535/en/

Contacts

Enquiries
Media: Dana Sultan-Rothman, media@compasspathways.com
Investors: Stephen Schultz, stephen.schultz@compasspathways.com, +1 401 290 7324

• FY2025 Pipeline Successes Set the Stage for Pivotal Product Launches
• Achieved Latest FY2025 Management Guidance
• Takeda is Entering a New Era & Transforming for Growth Acceleration

OSAKA, Japan–(BUSINESS WIRE)– Takeda (TOKYO:4502/NYSE:TAK) today announced financial results for the fiscal year 2025 (period ended March 31, 2026). The Company delivered solid results in line with its latest FY2025 Management Guidance, reflecting strong OPEX savings, mitigating revenue headwinds while continuing to invest in future growth.

Key Highlights for FY2025

• Revenue decreased by 1.7% YoY at actual exchange rates (AER), resulting from the loss of exclusivity for VYVANSE® which was partially mitigated by Growth and Launch Products. On a Core basis, Revenue decreased by 2.6% at Constant Exchange Rate (CER).
• Core Operating Profit increased by 0.8% YoY at AER and declined by 0.9% at CER, protected by OPEX savings, while still investing for growth.
• Reported Operating Profit increased by 19.3% YoY at AER, also reflecting a step-down in amortization expenses for VYVANSE and lower restructuring expenses.
• Core EPS increased by 5.2% YoY at AER and by 3.1% at CER, while reported EPS increased by 78.1% YoY.
• Adjusted Free Cash Flow amounted to JPY 684.5 billion, in line with forecast, and the Company ended fiscal year with strong cash balance.
• Delivered key milestones for oveporexton, rusfertide, and zasocitinib, with positive Phase 3 readouts; completed regulatory submissions for oveporexton and rusfertide, and launch preparations underway.

Takeda Chief Executive Officer (CEO)-elect, Julie Kim, commented:

“FY2025 was a pivotal year, validating the strength of our execution against demanding development and regulatory milestones, the resilience of our commercial portfolio and our strong position with three major launches planned in the next 12 months and the most robust late-stage pipeline in our history. Our growth roadmap is built around two strategic horizons: transforming for growth through near-term launches and strengthening competitiveness and accelerating growth by transitioning to a new cohort of blockbuster brands, together positioning us for long-term profitable growth and patient impact.”

Takeda Chief Financial Officer, Milano Furuta, commented:

“In FY2025, despite topline headwinds, we delivered solid profit and cash flow through disciplined cost control, while directing growth investment toward new product launches and the pipeline. In FY2026, we will continue to focus on transforming operations and protecting profitability while delivering successful launches and advancing our pipeline. Strong cash flow generation and deleveraging will support long-term investment for growth acceleration and ensure competitive returns for our shareholders.”

Full-year FY2026 Forecast and Guidance

Based on the current business outlook and planned investment profile, Takeda issued the following FY2026 forecast and management guidance.

Pipeline Achievements Set the Stage for Future Growth

Our three leading late-stage assets are positioned for regulatory approvals in the U.S. and other geographies in FY2026-2027. We expect this will be a pivotal period for launches and investment with clear near-term wins and proof points over the next 12–24 months.

oveporexton:

• Oveporexton is potentially a first-of-its-kind orexin agonist designed to address the underlying orexin deficiency that causes narcolepsy type 1.
• Granted Priority Review by the U.S. FDA, Takeda is preparing for a U.S. commercial launch for oveporexton in the second half of 2026 and has also completed regulatory filings in Japan and China.

rusfertide:

• Rusfertide is a potential first‑in‑class hepcidin mimetic that has demonstrated rapid, stable, and durable hematocrit control in patients with polycythemia vera, or PV, and has the potential to shift the standard of care in this blood cancer.
• Granted Priority Review by the U.S. FDA, Takeda is preparing for a U.S. commercial launch for rusfertide in the second half of 2026.

zasocitinib:

• Zasocitinib is poised to be a leading oral treatment option for psoriasis patients with the potential to significantly expand the oral segment in a growing psoriasis market.
• Takeda is making decisive investments to support a planned regulatory filing in 2026 and a commercial launch in the first half of 2027.

Capital Allocation and Shareholder Returns

Takeda maintains a disciplined capital allocation framework that prioritizes investments in new launches and R&D innovation to drive growth and enables the company to deliver returns to shareholders under its progressive dividend policy. In FY2025, the proposed annual dividend was JPY 200 per share, and year-end adjusted net debt/adjusted EBITDA was 2.6x.

Additional Information About Takeda’s FY2025 Results

Takeda will host a conference call for investors and analysts on Wednesday, May 13, 2026, at 7:00 PM JST / 6:00 AM EDT to discuss its full-year 2025 financial results.

A live webcast of the conference call, along with presentation materials, will be available on the investor relations section of Takeda’s website at www.takeda.com/investors. The presentation will contain further details on Takeda’s FY2025 results, commercial progress, pipeline updates, and other financial information, including key assumptions for the FY2026 forecast and definitions of non-IFRS measures.

About Takeda

Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit https://www.takeda.com.

Important Notice

For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this press release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

The product names appearing in this document are trademarks or registered trademarks owned by Takeda, or their respective owners.

Forward-Looking Statements

This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could”, “anticipates”, “estimates”, “projects”, “forecasts”, “outlook” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States and with respect to international trade relations; competitive pressures and developments; changes to applicable laws and regulations, including drug pricing, tax, tariff and other trade-related rules; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic; the success of our environmental sustainability efforts, in enabling us to reduce our greenhouse gas emissions or meet our other environmental goals; the extent to which our efforts to increase efficiency, productivity or cost-savings, such as the integration of digital technologies, including artificial intelligence, in our business or other initiatives to restructure our operations will lead to the expected benefits; and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/sec-filings-and-security-reports/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.

Financial information and Non-IFRS Measures

Takeda’s financial statements are prepared in accordance with International Financial Reporting Standards (“IFRS”).

This press release and materials distributed in connection with this press release include certain financial measures not presented in accordance with IFRS, such as Core Revenue, Core Operating Profit, Core Net Profit for the year attributable to owners of the Company, Core EPS, Constant Exchange Rate (“CER”) change, Net Debt, Adjusted Net Debt, EBITDA, Adjusted EBITDA, Free Cash Flow and Adjusted Free Cash Flow. Takeda’s management evaluates results and makes operating and investment decisions using both IFRS and non-IFRS measures included in this press release. These non-IFRS measures exclude certain income, cost and cash flow items which are included in, or are calculated differently from, the most closely comparable measures presented in accordance with IFRS. Takeda’s non-IFRS measures are not prepared in accordance with IFRS and such non-IFRS measures should be considered a supplement to, and not a substitute for, measures prepared in accordance with IFRS (which we sometimes refer to as “reported” measures). Investors are encouraged to review the definitions and reconciliations of non-IFRS measures to their most directly comparable IFRS measures, which are in the Financial Appendix appearing at the end of our FY2025 Q4 investor presentation (available at www.takeda.com/investors).

Medical information

This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.

Please refer to slide 14 of Takeda’s FY2025 Q4 investor presentation (available at https://www.takeda.com/investors/financial-results/quarterly-results/) for the definition of Growth & Launch Products.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260510786927/en/

Contacts

Investor Relations
Christopher O’Reilly
Christopher.oreilly@takeda.com
+81 (0) 90-6481-3412

Media Relations
Media_relations@takeda.com